NCT00243945

Brief Summary

The objective of this trial is to assess the effect of rotigotine (SPM 962) on the control of early morning motor impairment and sleep disorders in subjects with idiopathic PD. Subjects who meet eligibility criteria will begin treatment with rotigotine transdermal patches. Trial medication will be titrated to an optimal daily dose, or to the maximal dose. Following a Titration period of up to 8 weeks, subjects will be maintained on the optimal or maximal dose for 4 weeks. After the Maintenance period, subjects will have the option to enter into an open-label extension study. The first subject was enrolled in December 2004. The last subject was enrolled in April 2005 and the last subject visit was conducted in July 2005. This study is now closed

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Dec 2004

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2004

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2005

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 24, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 25, 2005

Completed
Last Updated

September 25, 2014

Status Verified

September 1, 2009

Enrollment Period

7 months

First QC Date

October 24, 2005

Last Update Submit

September 24, 2014

Conditions

IDIOPATHIC PARKINSON'S DISEASE

Outcome Measures

Primary Outcomes (1)

  • Motor performance; Sleep disorders; Clinical Global Impression; Patient Global Impression; Safety & Tolerability

Interventions

RotigotineDRUG

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Idiopathic Parkinson's disease

You may not qualify if:

  • Subject has previously participated in a trial with rotigotine.
  • Subject has participated in another trial of an investigational drug within the last 28 days or is currently participating in another trial of an investigational drug.
  • Subject discontinued from previous therapy with a dopamine agonist after an adequate length of treatment at an adequate dose due to lack of efficacy as assessed by the investigator.
  • Subject has had prior therapy with a dopamine agonist within 28 days prior to Baseline.
  • Subject is receiving therapy with controlled-release levodopa within 28 days prior to baseline or is receiving therapy with tolcapone.
  • Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Visit 2: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (including atypical), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine.
  • Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the 6 months prior to baseline.
  • Subject has atypical Parkinsonian syndromes (including drug-induced Parkinsonian syndromes).
  • Subject has a history of atopic eczema and/or active skin disease, such as atopic eczema.
  • Presence of dementia, active psychosis, or hallucinations (not due to antiparkinsonian medication).
  • Subject is receiving CNS therapy (eg, sedatives, hypnotics, selective serotonin reuptake inhibitors \[SSRIs\], anxiolytics, other sleep-modifying medication) unless dose has been stable daily for at least 28 days prior to baseline and is likely to remain stable for the duration of the trial.
  • Subject has a history of seizures or stroke within 1 year, or a history of myocardial infarction within the last 6 months prior to enrollment.
  • Subject has neoplastic disease requiring therapy within 12 months prior to enrollment.
  • Presence of clinically relevant hepatic dysfunction.
  • Presence of clinically relevant renal dysfunction.
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Schwarz

Monheim, Germany

Location

Related Publications (1)

  • Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm (Vienna). 2010 Dec;117(12):1395-9. doi: 10.1007/s00702-010-0506-4. Epub 2010 Nov 16.

    PMID: 21080009RESULT

MeSH Terms

Conditions

Parkinson Disease

Interventions

rotigotine

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • UCB Clinical Trial Call Center

    UCB Pharma

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 24, 2005

First Posted

October 25, 2005

Study Start

December 1, 2004

Primary Completion

July 1, 2005

Study Completion

July 1, 2005

Last Updated

September 25, 2014

Record last verified: 2009-09

Locations

DE(1)